Beneficial effects of coronary venous retroinfusion but not left atrial administration of superoxide dismutase on myocardial necrosis in pigs
- PMID: 2040328
- DOI: 10.1093/oxfordjournals.eurheartj.a059915
Beneficial effects of coronary venous retroinfusion but not left atrial administration of superoxide dismutase on myocardial necrosis in pigs
Abstract
The efficacy of coronary venous versus left atrial administration of superoxide dismutase was studied in 24 open chest pigs which had 60 min of left anterior descending coronary artery occlusion followed by 3 h reperfusion. The pigs were randomly assigned to three treatment protocols: group A (n = 8) superoxide dismutase (5 mg kg-1) was infused into the great cardiac vein for 30 min beginning 15 min before reperfusion; group B (n = 8) superoxide dismutase (5 mg kg-1) was infused into the left atrium in a similar manner to group A; group C (n = 8) bovine serum albumin (5 mg kg-1) was infused into the great cardiac vein in the same manner as group A. Infarct size, expressed as percent of area at risk, was significantly smaller in group A (28.2 +/- 13.0%) than groups B (58.7 +/- 8.3%) and C (61.6 +/- 7.2%) (P less than 0.05). The results indicate that retroinfusion of superoxide dismutase into the great cardiac vein before reperfusion may be an effective treatment for the prevention of reperfusion injury, even in the absence of a well developed coronary collateral circulation. Antegrade (left atrial) administration of the same amount of superoxide dismutase did not decrease infarct size in pigs. The most likely explanation for this difference in efficacy is that drug delivery with left atrial administration is dependent on antegrade flow with reperfusion which is less reliable and less efficient than coronary venous retroinfusion. The latter provides a predictably high concentration of superoxide dismutase to the jeopardized myocardium during the period of ischaemia before reperfusion.
Similar articles
-
Beneficial effects of coronary venous retroinfusion of superoxide dismutase and catalase on reperfusion arrhythmias, myocardial function, and infarct size in dogs.J Cardiovasc Pharmacol. 1989 Sep;14(3):396-404. doi: 10.1097/00005344-198909000-00007. J Cardiovasc Pharmacol. 1989. PMID: 2476618
-
Pharmacokinetic analysis of coronary venous retroinfusion: a comparison with anterograde coronary artery drug administration using metoprolol as a tracer.J Am Coll Cardiol. 1991 Aug;18(2):603-12. doi: 10.1016/0735-1097(91)90620-o. J Am Coll Cardiol. 1991. PMID: 1856430
-
Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model.J Cardiovasc Pharmacol. 1996 Jul;28(1):134-41. doi: 10.1097/00005344-199607000-00020. J Cardiovasc Pharmacol. 1996. PMID: 8797147
-
Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase.Circ Res. 1984 Mar;54(3):277-85. doi: 10.1161/01.res.54.3.277. Circ Res. 1984. PMID: 6697450
-
Failure of superoxide dismutase to limit size of myocardial infarction after 40 minutes of ischemia and 4 days of reperfusion in dogs.Circulation. 1987 Jun;75(6):1237-48. doi: 10.1161/01.cir.75.6.1237. Circulation. 1987. PMID: 3568330
Cited by
-
Mitochondrial therapeutics for cardioprotection.Curr Pharm Des. 2011;17(20):2017-35. doi: 10.2174/138161211796904777. Curr Pharm Des. 2011. PMID: 21718247 Free PMC article. Review.
-
Pharmacokinetic analysis of coronary sinus retroinfusion in pigs. Ischemic myocardial concentrations in the left circumflex coronary arterial area using metoprolol as a tracer.Cardiovasc Drugs Ther. 1991 Dec;5(6):1005-10. doi: 10.1007/BF00143528. Cardiovasc Drugs Ther. 1991. PMID: 1801888
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources